Abstract
Purpose
The purpose of this study is to clarify the impact of P-gp and Oatp on intestinal absorption of the β1-adrenoceptor antagonist talinolol.
Methods
P-gp-mediated transport was measured in LLC-PK1/MDR1 cells. Oatp-mediated uptake was evaluated with Xenopus oocytes expressing Oatp1a5. Rat intestinal permeability was measured by the in situ closed loop method. In vivo absorption was pharmacokinetically assessed by measuring plasma concentration after oral administration in rats.
Results
In LLC-PK1/MDR1 cells, the permeability of talinolol was markedly higher in the secretory direction than in the absorptive one. The uptake of talinolol by Xenopus oocytes expressing Oatp1a5 was significantly increased compared with that by water-injected oocytes. Naringin inhibited talinolol uptake by Oatp1a5 (IC 50 = 12.7 μM). The reported IC 50 value of naringin for P-gp-mediated transport of talinolol is approximately 2,000 μM. Rat intestinal permeability of talinolol was significantly decreased in the presence of 200 μM naringin, but was significantly increased by 2,000 μM naringin. Similar results were obtained in in vivo absorption studies in rats.
Conclusion
The absorption behavior of talinolol can be explained by the involvement of both P-gp and Oatp, based on characterization of talinolol transport by Oatp1a5 and P-gp, and the effects of naringin.
Similar content being viewed by others
Abbreviations
- AP:
-
Apical
- AUC:
-
Area under the plasma concentration–time curve
- BL:
-
Basolateral
- DDI:
-
Drug–drug interactions
- GFJ:
-
Grapefruit juice
- MDR:
-
Multidrug resistance
- OATP/Oatp:
-
Organic anion transporting polypeptide
- P app :
-
Apparent permeability
- P-gp:
-
P-glycoprotein
References
P. Macheras, and P. Argyrakis. Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity. Pharm. Res. 14:842–847 (1997). doi:10.1023/A:1012183313218.
H. Zhou. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J. Clin. Pharmacol. 43:211–227 (2003). doi:10.1177/0091270002250613.
A. Tsuji, and I. Tamai. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13:963–977 (1996). doi:10.1023/A:1016086003070.
K. Naruhashi, I. Tamai, N. Inoue, H. Muraoka, Y. Sai, N. Suzuki, and A. Tsuji. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J. Pharm. Pharmacol. 53:699–709 (2001). doi:10.1211/0022357011775820.
T. Tani, L. K. Gram, H. Arakawa, A. Kikuchi, M. Chiba, Y. Ishii, B. Steffansen, and I. Tamai. Involvement of organic anion transporting polypeptide 1a5 (Oatp1a5) in the intestinal absorption of endothelin receptor antagonist in rats. Pharm. Res. 25:1085–1091 (2008). doi:10.1007/s11095-007-9472-4.
Y. Tanigawara. Role of P-glycoprotein in drug disposition. Ther. Drug. Monit. 22:137–140 (2000). doi:10.1097/00007691-200002000-00029.
A. H. Schinkel. P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv. Drug Deliv. Rev. 36:179–194 (1999). doi:10.1016/S0169-409X(98)00085-4.
M. F. Fromm. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38:69–74 (2000).
Y. Shirasaka, T. Sakane, and S. Yamashita. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J. Pharm. Sci. 97:553–565 (2008). doi:10.1002/jps.21114.
Y. Shirasaka, Y. Masaoka, M. Kataoka, S. Sakuma, and S. Yamashita. Scaling of in vitro membrane permeability to predict P-glycoprotein-mediated drug absorption in vivo. Drug Metab. Dispos. 36:916–922 (2008). doi:10.1124/dmd.107.020040.
M. Verschraagen, C. H. Koks, J. H. Schellens, and J. H. Beijnen. P-glycoprotein system as a determinant of drug interactions: the case of digoxin–verapamil. Pharmacol. Res. 40:301–306 (1999). doi:10.1006/phrs.1999.0535.
D. K. Yu. The contribution of P-glycoprotein to pharmacokinetic drug–drug interactions. J. Clin. Pharmacol. 39:1203–1211 (1999). doi:10.1177/00912709922012006.
S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan, and M. M. Gottesman. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361–398 (1999). doi:10.1146/annurev.pharmtox.39.1.361.
B. Trausch, R. Oertel, K. Richter, and T. Gramatté. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm. Drug Dispos. 16:403–414 (1995). doi:10.1002/bdd.2510160505.
K. Westphal, A. Weinbrenner, T. Giessmann, M. Stuhr, G. Franke, M. Zschiesche, R. Oertel, B. Terhaag, H. K. Kroemer, and W. Siegmund. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther. 68:6–12 (2000). doi:10.1067/mcp.2000.107579.
W. Weitschies, A. Bernsdorf, T. Giessmann, M. Zschiesche, C. Modess, V. Hartmann, C. Mrazek, D. Wegner, S. Nagel, and W. Siegmund. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm. Res. 22:728–735 (2005). doi:10.1007/s11095-005-2588-5.
U. Wetterich, H. Spahn-Langguth, E. Mutschler, B. Terhaag, W. Rösch, and P. Langguth. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:514–522 (1996). doi:10.1023/A:1016029601311.
M. Zschiesche, G. L. Lemma, K. J. Klebingat, G. Franke, B. Terhaag, A. Hoffmann, T. Gramatté, H. K. Kroemer, and W. Siegmund. Stereoselective disposition of talinolol in man. J. Pharm. Sci. 91:303–311 (2002). doi:10.1002/jps.10054.
H. Spahn-Langguth, and P. Langguth. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12:361–367 (2001). doi:10.1016/S0928-0987(00)00191-3.
U. I. Schwarz, D. Seemann, R. Oertel, S. Miehlke, E. Kuhlisch, M. F. Fromm, R. B. Kim, D. G. Bailey, and W. Kirch. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther. 77:291–301 (2005). doi:10.1016/j.clpt.2004.11.111.
W. V. de Castro, S. Mertens-Talcott, H. Derendorf, and V. Butterweck. Grapefruit juice–drug interactions: grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J. Pharm. Sci. 96:2808–2817 (2007). doi:10.1002/jps.20975.
G. K. Dresser, D. G. Bailey, B. F. Leake, U. I. Schwarz, P. A. Dawson, D. J. Freeman, and R. B. Kim. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71:11–20 (2002). doi:10.1067/mcp.2002.121152.
D. G. Bailey, G. K. Dresser, B. F. Leake, and R. B. Kim. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81:495–502 (2007). doi:10.1038/sj.clpt.6100104.
I. Tamai, J. Nezu, H. Uchino, Y. Sai, A. Oku, M. Shimane, and A. Tsuji. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273:251–260 (2000). doi:10.1006/bbrc.2000.2922.
D. Kobayashi, T. Nozawa, K. Imai, J. Nezu, A. Tsuji, and I. Tamai. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 306:703–708 (2003). doi:10.1124/jpet.103.051300.
T. Nozawa, K. Imai, J. Nezu, A. Tsuji, and I. Tamai. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308:438–445 (2004). doi:10.1124/jpet.103.060194.
T. Maeda, K. Takahashi, N. Ohtsu, T. Oguma, T. Ohnishi, R. Atsumi, and I. Tamai. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol. Pharm. 4:85–94 (2007). doi:10.1021/mp060082j.
I. Tamai, A. Saheki, R. Saitoh, Y. Sai, I. Yamada, and A. Tsuji. Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters. J. Pharmacol. Exp. Ther. 283:108–115 (1997).
A. Kikuchi, T. Nozawa, T. Wakasawa, T. Maeda, and I. Tamai. Transporter-mediated intestinal absorption of fexofenadine in rats. Drug. Metab. Pharmacokinet. 21:308–314 (2006). doi:10.2133/dmpk.21.308.
M. Ofer, P. Langguth, and H. Spahn-Langguth. Bidirectional membrane transport: simulations of transport inhibition in uptake studies explain data obtained with flavonoids. Eur. J. Pharm. Sci. 29:251–258 (2006). doi:10.1016/j.ejps.2006.06.010.
U. I. Schwarz, T. Gramatté, J. Krappweis, R. Oertel, and W. Kirch. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther. 38:161–167 (2000).
A. Hanafy, P. Langguth, and H. Spahn-Langguth. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur. J. Pharm. Sci. 12:405–415 (2001). doi:10.1016/S0928-0987(00)00195-0.
H. Spahn-Langguth, G. Baktir, A. Radschuweit, A. Okyar, B. Terhaag, P. Ader, A. Hanafy, and P. Langguth. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:16–24 (1998).
U. I. Schwarz, T. Gramatté, J. Krappweis, A. Berndt, R. Oertel, O. von Richter, and W. Kirch. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin. Pharmacol. Ther. 65:283–290 (1999). doi:10.1016/S0009-9236(99)70107-4.
Y. Shitara, D. Sugiyama, H. Kusuhara, Y. Kato, T. Abe, P. J. Meier, T. Itoh, and Y. Sugiyama. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm. Res. 19:147–153 (2002). doi:10.1023/A:1014264614637.
U. Fagerholm, A. Lindahl, and H. Lennernäs. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J. Pharm. Pharmacol. 49:687–690 (1997).
C. Hilgendorf, H. Spahn-Langguth, M. Rhedin, C. G. Regårdh, B. Löwenadler, and P. Langguth. Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport. Mol. Pharm. 2:64–73 (2005). doi:10.1021/mp049931y.
L. M. Augustine, R. J. Markelewicz, K. Boekelheide, and N. J. Cherrington. Xenobiotic and endobiotic transporter mRNA expression in the blood–testis barrier. Drug. Metab. Dispos. 33:182–189 (2005). doi:10.1124/dmd.104.001024.
Y. Koitabashi, T. Kumai, N. Matsumoto, M. Watanabe, S. Sekine, Y. Yanagida, and S. Kobayashi. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci. 78:2852–2859 (2006). doi:10.1016/j.lfs.2005.11.006.
H. C. Walters, A. L. Craddock, H. Fusegawa, M. C. Willingham, and P. A. Dawson. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am. J. Physiol. Gastrointest. Liver Physiol. 279:G1188–1200 (2000).
W. V. de Castro, S. Mertens-Talcott, A. Rubner, V. Butterweck, and H. Derendorf. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice–drug interaction studies. J. Agric. Food. Chem. 54:249–255 (2006). doi:10.1021/jf0516944.
Y. Masaoka, Y. Tanaka, M. Kataoka, S. Sakuma, and S. Yamashita. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur. J. Pharm. Sci. 29:240–250 (2006). doi:10.1016/j.ejps.2006.06.004.
F. Tourniaire, M. Hassan, M. André, O. Ghiringhelli, C. Alquier, and M. J. Amiot. Molecular mechanisms of the naringin low uptake by intestinal Caco-2 cells. Mol. Nutr. Food Res. 49:957–962 (2005). doi:10.1002/mnfr.200500088.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shirasaka, Y., Li, Y., Shibue, Y. et al. Concentration-Dependent Effect of Naringin on Intestinal Absorption of β1-Adrenoceptor Antagonist Talinolol Mediated by P-Glycoprotein and Organic Anion Transporting Polypeptide (Oatp). Pharm Res 26, 560–567 (2009). https://doi.org/10.1007/s11095-008-9771-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-008-9771-4